Opus Genetics is trading 5.11% down now at $3.90, with no new company-specific announcement identified on August 26, 2026, leaving the catalyst unclear.
- Latest reported developments were August 6 second-quarter results and August 3 completion of enrollment in the OPGx-LCA5 Phase 3 trial.
- Biotechnology is stronger overall, while major indexes are slightly lower; those dated updates do not clearly explain today’s decline.